AU2003220079A1 - Uses of monoclonal antibody 8h9 - Google Patents

Uses of monoclonal antibody 8h9

Info

Publication number
AU2003220079A1
AU2003220079A1 AU2003220079A AU2003220079A AU2003220079A1 AU 2003220079 A1 AU2003220079 A1 AU 2003220079A1 AU 2003220079 A AU2003220079 A AU 2003220079A AU 2003220079 A AU2003220079 A AU 2003220079A AU 2003220079 A1 AU2003220079 A1 AU 2003220079A1
Authority
AU
Australia
Prior art keywords
monoclonal antibody
monoclonal
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003220079A
Other languages
English (en)
Other versions
AU2003220079A8 (en
Inventor
Nai-Kong V. Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/097,558 external-priority patent/US7737258B2/en
Priority claimed from US10/273,762 external-priority patent/US7666424B2/en
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU2003220079A8 publication Critical patent/AU2003220079A8/xx
Publication of AU2003220079A1 publication Critical patent/AU2003220079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
AU2003220079A 2002-03-08 2003-03-06 Uses of monoclonal antibody 8h9 Abandoned AU2003220079A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/097,558 US7737258B2 (en) 2000-10-18 2002-03-08 Uses of monoclonal antibody 8H9
US10/097,558 2002-03-08
PCT/US2002/033331 WO2003033670A2 (fr) 2001-10-17 2002-10-17 Procede de preparation d'anticorps monocatenaires
US10/273,762 US7666424B2 (en) 2001-10-17 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies
US10/273,762 2002-10-17
AU2002362846 2002-10-17
PCT/US2003/007004 WO2003075846A2 (fr) 2002-03-08 2003-03-06 Utilisations d'anticorps 8h9 monoclonaux

Publications (2)

Publication Number Publication Date
AU2003220079A8 AU2003220079A8 (en) 2003-09-22
AU2003220079A1 true AU2003220079A1 (en) 2003-09-22

Family

ID=27808456

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003220079A Abandoned AU2003220079A1 (en) 2002-03-08 2003-03-06 Uses of monoclonal antibody 8h9

Country Status (3)

Country Link
AU (1) AU2003220079A1 (fr)
CA (1) CA2478082C (fr)
WO (1) WO2003075846A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
CA2508519A1 (fr) * 2002-12-02 2004-06-17 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Immunotoxine recombinante et son utilisation dans le traitement de tumeurs
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
EP2121008A4 (fr) * 2007-03-22 2010-03-31 Sloan Kettering Inst Cancer Utilisations de l'anticorps monoclonal 8h9
EA201401134A1 (ru) 2011-02-11 2015-05-29 Мемориал Слоан-Кеттеринг Кэнсер Сентер Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
WO2012135854A2 (fr) 2011-04-01 2012-10-04 Memorial Sloan-Kettering Cancer Center Anticorps contre des peptides cytosoliques
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
US9963509B2 (en) 2014-12-23 2018-05-08 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
CA3103629A1 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activite immunitaire par modulation de facteurs de signalisation post-cellulaires
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
EP4022313A1 (fr) 2019-08-30 2022-07-06 Y-Mabs Therapeutics, Inc. Évaluation immunohistochimique de l'expression de b7-h3
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CA3214085A1 (fr) 2021-03-31 2022-10-06 Darby Rye Schmidt Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer

Also Published As

Publication number Publication date
AU2003220079A8 (en) 2003-09-22
CA2478082C (fr) 2016-02-02
CA2478082A1 (fr) 2003-09-18
WO2003075846A2 (fr) 2003-09-18
WO2003075846A3 (fr) 2005-08-11

Similar Documents

Publication Publication Date Title
EP1572077A3 (fr) Utilisations d'anticorps 8h9 monoclonaux
EP1572077A4 (fr) Utilisations d'anticorps 8h9 monoclonaux
AU2003220079A1 (en) Uses of monoclonal antibody 8h9
AU2003264009A1 (en) Humanized rabbit antibodies
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
AU2003217912A1 (en) Antibody optimization
AU2003242024A1 (en) Method of constructing antibody
AU2003259294A1 (en) Humanized antibodies against human 4-1bb
EP1399187A4 (fr) Utilisations d'anticorps monoclonal 8h9
EP1391464A4 (fr) Anticorps monoclonal anti-cd40
AU2002256895A1 (en) Anti-TRAIL-R antibodies
HK1078589A1 (en) Anti-human tenascin monoclonal antibody
EP1607404A4 (fr) Anticorps monoclonal et hybridome produisant celui-ci
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
AU2002365649A1 (en) Anti-dota antibody
AU2003277832A1 (en) Humanized tissue factor antibodies
AU2003229799A1 (en) Novel humanized anti-vap-1 monoclonal antibody
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin
AU2003262638A1 (en) Biotinylation of proteins
AU2002215383A1 (en) Uses of monoclonal antibody 8h9
AU2002242447A1 (en) Use of polyclonal immunoglobulins
AU2003271093A1 (en) Antigen recognizing antibody
AU2001281099A1 (en) Production of human monoclonal antibodies
AU2003241827A1 (en) Antibody capable of recognizing 8-nitroguanine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase